| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | 0.058 | 0.06 |
| mRNA | CHIR-99021 | GDSC1000 | pan-cancer | AAC | 0.058 | 0.06 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | 0.059 | 0.06 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | -0.064 | 0.06 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.069 | 0.06 |
| mRNA | XAV-939 | GDSC1000 | pan-cancer | AAC | 0.062 | 0.06 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.059 | 0.07 |
| mRNA | S-Trityl-L-cysteine | FIMM | pan-cancer | AAC | -0.35 | 0.07 |
| mRNA | BIRB 0796 | CTRPv2 | pan-cancer | AAC | -0.068 | 0.07 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | -0.11 | 0.07 |